• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxolanes Oxolanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Oxolanes

Introduction to [(Oxolan-2-yl)methyl](pentan-2-yl)amine (CAS No. 1020970-80-2)

[(Oxolan-2-yl)methyl](pentan-2-yl)amine, with the CAS number 1020970-80-2, is a versatile organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structure, which combines an oxolane ring with a pentyl amine moiety, making it a valuable candidate for various applications in drug discovery and development.

The molecular formula of [(Oxolan-2-yl)methyl](pentan-2-yl)amine is C₁₀H₂₁N, and its molecular weight is approximately 159.3 g/mol. The compound's structure consists of a five-membered oxolane ring attached to a methyl group, which is further connected to a pentan-2-yl amine group. This structural arrangement imparts specific chemical properties that are crucial for its potential biological activities.

In recent years, the study of [(Oxolan-2-yl)methyl](pentan-2-yl)amine has been driven by its potential as a lead compound in the development of new therapeutic agents. Research has shown that this compound exhibits promising pharmacological properties, including anti-inflammatory and neuroprotective effects. These properties make it an attractive candidate for the treatment of various diseases and conditions.

Anti-inflammatory Properties: One of the key areas of research involving [(Oxolan-2-yl)methyl](pentan-2-yl)amine is its anti-inflammatory activity. Studies have demonstrated that this compound can effectively inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. This inhibition is crucial in reducing inflammation and can be beneficial in treating inflammatory diseases such as arthritis and inflammatory bowel disease (IBD).

Neuroprotective Effects: Another significant area of interest is the neuroprotective potential of [(Oxolan-2-yl)methyl](pentan-2-yl)amine. Research has shown that this compound can protect neurons from oxidative stress and apoptosis, which are common mechanisms underlying neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The neuroprotective effects are attributed to its ability to modulate key signaling pathways involved in cell survival and death.

Synthetic Routes: The synthesis of [(Oxolan-2-yl)methyl](pentan-2-yl)amine has been extensively studied, and several efficient synthetic routes have been developed. One common approach involves the reaction of an oxolane derivative with a pentan-2-yloxyamine under mild conditions. These synthetic methods are scalable and can be adapted for large-scale production, making the compound accessible for further research and development.

Clinical Trials: While preclinical studies have shown promising results, the clinical evaluation of [(Oxolan-2-yl)methyl](pentan-2-yl)amine is still in its early stages. Initial clinical trials are focused on assessing the safety and efficacy of this compound in treating specific conditions. Preliminary data from these trials have been encouraging, with no significant adverse effects reported at therapeutic doses.

FUTURE DIRECTIONS: The future prospects for [(Oxolan-2-y-lmethyl)(pentan-2-y-l)amine] are promising. Ongoing research aims to optimize its pharmacological properties through structural modifications and to explore its potential in combination therapies. Additionally, efforts are being made to develop more efficient and cost-effective synthetic methods to facilitate large-scale production.

In conclusion, [(Oxolan-2-y-lmethyl)(pentan - 2 - yl)amine] (CAS No. 1020970 - 80 - 2) represents a significant advancement in the field of medicinal chemistry. Its unique structure and promising biological activities make it a valuable candidate for further research and development in the treatment of various diseases. As research continues to uncover new insights into its mechanisms of action, it is likely that this compound will play an increasingly important role in pharmaceutical innovation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)